BIIB
Lecanemab shows strong efficacy in early Alzheimer’s, especially for patients with α-Syn co-pathology.
LEQEMBI shows strong real-world durability and safety in early Alzheimer's across 560 U.S. patients.
Biogen and UCB’s lupus drug shows strong Phase 3 efficacy, but remains unapproved and long-dated.
Biogen launches at-home Alzheimer's injection, but financial impact remains unquantified.
This is a routine executive hire with no immediate investment impact or financial disclosure.
Strong clinical data, but no financials—investors lack evidence of commercial traction or profit.
Biogen’s Alzheimer’s drug shows promise, but commercial payoff is years and risks away.
This is a routine legal settlement, not a signal of business strength or weakness.
Biogen touts Alzheimer’s progress, but offers little hard data or near-term financial clarity.
Biogen’s SMA drug gets FDA boost, but real proof and profits are years away.
Biogen’s lupus drug shows promise, but real investor payoff is still years away.
Biogen’s nephrology update is clinically solid but offers little for investors seeking financial clarity.
Promising clinical data, but commercial payoff is distant and far from guaranteed.
Biogen and Denali’s Parkinson’s drug failed, and the program is being shut down.
Biogen’s Apellis buy adds revenue, but future gains are mostly unproven and years away.
Regulatory progress is real, but commercial impact and timelines remain highly uncertain.